ENTRY       D09763                      Drug
NAME        Dapagliflozin propanediol (USAN);
            Dapagliflozin propylene glycolate hydrate (JAN);
            Dapagliflozin propandiol monohydrate;
            Forxiga (TN);
            Farxiga (TN)
PRODUCT     FARXIGA (A-S Medication Solutions)
            FARXIGA (AstraZeneca Pharmaceuticals LP)
            FARXIGA (Cardinal Health 107)
FORMULA     C21H25ClO6. C3H8O2. H2O
EXACT_MASS  502.197
MOL_WEIGHT  502.9823
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG01794  SGLT2 inhibitor
            Metabolizing enzyme substrate
             DG02924  UGT substrate
              DG03188  UGT1A9 substrate
REMARK      Therapeutic category: 2190 3969 3999
            ATC code: A10BK01
            Chemical structure group: DG00122
            Product (DG00122): D09763<JP/US>
            Product (mixture): D10586<US> D10826<US>
EFFICACY    Antidiabetic, SGLT-2 inhibitor
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
COMMENT     Phlorizin derivative
TARGET      SLC5A2 (SGLT2) [HSA:6524] [KO:K14382]
METABOLISM  Enzyme: UGT1A9 [HSA:54600]
INTERACTION  
STR_MAP     map07051  Antidiabetics
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
                 A10BK01 Dapagliflozin
                  D09763  Dapagliflozin propanediol (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Agents
               Sodium-Glucose Co-Transporter 2 (SGLT2) Inhbitor
                Dapagliflozin
                 D09763  Dapagliflozin propanediol (USAN)
             Cardiovascular Agents
              Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i)
               Dapagliflozin
                D09763  Dapagliflozin propanediol (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               219  Miscellaneous
                2190  Miscellaneous
                 D09763  Dapagliflozin propanediol (USAN); Dapagliflozin propylene glycolate hydrate (JAN)
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               396  Antidiabetic agents
                3969  Others
                 D09763  Dapagliflozin propanediol (USAN); Dapagliflozin propylene glycolate hydrate (JAN)
               399  Miscellaneous
                3999  Others
                 D09763  Dapagliflozin propanediol (USAN); Dapagliflozin propylene glycolate hydrate (JAN)
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG01794  SGLT2 inhibitor
                DG00122  Dapagliflozin
                 D09763  Dapagliflozin propanediol
             Metabolizing enzyme substrate
              DG02924  UGT substrate
               DG03188  UGT1A9 substrate
                DG00122  Dapagliflozin
                 D09763  Dapagliflozin propanediol
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG01794  SGLT2 inhibitor
               D09763  Dapagliflozin propanediol
              DG02044  Hypoglycemic agent
               D09763  Dapagliflozin propanediol
            Target-based classification of drugs [BR:br08310]
             Transporters
              Solute carrier family
               SLC5
                SLC5A2 (SGLT2)
                 D09763  Dapagliflozin propanediol (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09763
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09763
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09763
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09763
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09763
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG01794  SGLT2 inhibitor
                DG00122  Dapagliflozin
             Metabolizing enzyme substrate
              DG02924  UGT substrate
               DG03188  UGT1A9 substrate
                DG00122  Dapagliflozin
DBLINKS     CAS: 960404-48-2
            PubChem: 124490503
            ChEBI: 85079
            LigandBox: D09763
ATOM        34
            1   C8y C     8.1200  -20.5100
            2   C8x C     8.1200  -21.9100
            3   C8x C     9.3100  -22.6100
            4   C8y C    10.5700  -21.9100
            5   C8y C    10.5700  -20.5100
            6   C8x C     9.3100  -19.8100
            7   C1b C    11.7600  -19.8100
            8   C8y C    13.0200  -20.5100
            9   C8x C    13.0200  -21.9100
            10  C8x C    14.2100  -22.6100
            11  C8y C    15.4000  -21.9100
            12  C8x C    15.4000  -20.5100
            13  C8x C    14.2100  -19.8100
            14  X   Cl   11.7600  -22.6100
            15  O2a O    16.5900  -22.6100
            16  C1b C    17.7800  -21.9100
            17  C1a C    18.9700  -22.6100
            18  C1y C     6.9300  -19.8100
            19  O2x O     6.9300  -18.4100
            20  C1y C     5.6700  -17.7100
            21  C1y C     4.4800  -18.4100
            22  C1y C     4.4800  -19.8100
            23  C1y C     5.6700  -20.5100
            24  O1a O     5.6700  -21.9100
            25  O1a O     3.2900  -17.7100
            26  O1a O     3.2900  -20.5100
            27  C1b C     5.6700  -16.3100
            28  O1a O     6.9300  -15.6100
            29  C1a C    15.9600  -15.8200
            30  C1c C    17.1724  -16.5200
            31  C1b C    18.3679  -15.8296
            32  O1a O    17.1725  -17.9198
            33  O1a O    19.5553  -16.5151
            34  O0  O    20.7200  -20.0200
BOND        34
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 2
            10    9  10 1
            11   10  11 2
            12   11  12 1
            13   12  13 2
            14    8  13 1
            15    4  14 1
            16   11  15 1
            17   15  16 1
            18   16  17 1
            19   18   1 1 #Up
            20   18  19 1
            21   19  20 1
            22   20  21 1
            23   21  22 1
            24   22  23 1
            25   18  23 1
            26   23  24 1 #Down
            27   21  25 1 #Down
            28   22  26 1 #Up
            29   20  27 1 #Up
            30   27  28 1
            31   29  30 1
            32   30  31 1
            33   30  32 1
            34   31  33 1
///
